Mesoblast Limited (MESO)
NASDAQ: MESO · IEX Real-Time Price · USD
6.45
-0.33 (-4.87%)
At close: Jul 2, 2024, 4:00 PM
6.55
+0.10 (1.55%)
After-hours: Jul 2, 2024, 5:05 PM EDT
Mesoblast Revenue
Mesoblast had revenue of $7.25M in the twelve months ending December 31, 2023, down -10.69% year-over-year. In the fiscal year ending June 30, 2023, Mesoblast had annual revenue of $7.50M, a decrease of -26.54%.
Revenue (ttm)
$7.25M
Revenue Growth
-10.69%
P/S Ratio
101.49
Revenue / Employee
$87,386
Employees
83
Market Cap
736.10M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
| Jun 30, 2019 | 16.72M | -619.00K | -3.57% |
| Jun 30, 2018 | 17.34M | 14.93M | 618.95% |
| Jun 30, 2017 | 2.41M | -40.14M | -94.33% |
| Jun 30, 2016 | 42.55M | 22.79M | 115.31% |
| Jun 30, 2015 | 19.76M | -3.63M | -15.52% |
| Jun 30, 2014 | 23.39M | -5.91M | -20.17% |
| Jun 30, 2013 | 29.30M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GeneDx Holdings | 221.85M |
| Cytek Biosciences | 200.79M |
| Aurinia Pharmaceuticals | 191.41M |
| Harrow Health | 138.68M |
| CureVac | 64.13M |
| Perspective Therapeutics | -304.00K |
MESO News
- 1 day ago - Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week - GlobeNewsWire
- 4 weeks ago - Mesoblast Corporate Presentation at Investor Conference - GlobeNewsWire
- 2 months ago - Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024 - GlobeNewsWire
- 3 months ago - United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) - GlobeNewsWire
- 3 months ago - Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer - GlobeNewsWire
- 4 months ago - United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) - GlobeNewsWire
- 4 months ago - Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 - GlobeNewsWire
- 4 months ago - Mesoblast Financial Results and Corporate Update Webcast - GlobeNewsWire